CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. The rise in the number of candidates for gene therapy coupled with the swift
development
4.1.2. Ongoing research into viral vector-based gene and cell therapies
4.1.3. Increase in the number of clinical studies
4.1.4. Availability of funding for the development of gene therapy
4.1.5. High prevalence of genetic disorders, cancer, and infectious diseases
4.2. Market Restraints & Challenges
4.2.1. The high cost of gene therapies
4.2.2. Short shelf-life of viral vectors
4.2.3. Possible insertional mutagenesis and other unwanted outcomes
4.3. Market Opportunities
4.3.1. Technological advancements of vector production
CHAPTER 5. GLOBAL VIRAL VECTOR MANUFACTURING MARKET – BY TYPE
5.1. Retroviral Vectors
5.1.1. Lentiviral Vectors
5.1.2. Gamma-Retroviral Vectors
5.2. Adenoviral Vectors
5.3. Adeno-Associated Viral Vectors
5.4. Others
CHAPTER 6. GLOBAL VIRAL VECTOR MANUFACTURING MARKET – BY
DISEASE
6.1. Cancer
6.2. Genetic Disorders
6.3. Infectious Disorders
6.4. Others
CHAPTER 7. GLOBAL VIRAL VECTOR MANUFACTURING MARKET – BY
APPLICATION
7.1. Gene Therapy
7.2. Vaccinology
CHAPTER 8. GLOBAL VIRAL VECTOR MANUFACTURING MARKET – BY END
USER
8.1. Pharmaceutical & Biotechnology Companies
8.2. Research Institutes
CHAPTER 9. GLOBAL VIRAL VECTOR MANUFACTURING MARKET - BY
GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. APAC
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10. GLOBAL VIRAL VECTOR MANUFACTURING MARKET COMPANY
PROFILES
10.1. Kaneka Eurogentec S.A.
10.2. FinVector Vision Therapies
10.3. Brammer Bio LLC
10.4. Oxford BioMedica
10.5. Merck KGaA
10.6. Novasep Inc.
10.7. Cell and Gene Therapy Catapult
10.8. Cobra Biologics Limited
10.9. Spark Therapeutics
10.10. QIAGEN N.V.
10.11. Uniqure N.V.
10.12. 4D Molecular Therapeutics LLC
10.13. Renova Therapeutics
10.14. Shenzhen SiBiono GeneTech Co., Ltd.
10.15. Sanofi
CHAPTER 11. GLOBAL VIRAL VECTOR MANUFACTURING MARKET
COMPETITIVE LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12. MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13. APPENDIX
13.1. List of Tables
13.2. List of Figures
